An observational study in Aspirin-exacerbated Respiratory Disease and Nasal Polyp, sponsored by University of South Florida. Completed at 1 site in United States. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2014-10-07.
Sponsored by University of South Florida · Observational
We hypothesize that the miRNA expression in subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) differs from the miRNA expressed in subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD).
Nasal epithelial tissue will be collected from the inferior nasal turbinates of ten subjects with nasal polyps and AERD disease and from the inferior turbinates of ten subjects with nasal polyps but without AERD. A rhinoprobe™ will be used to collect this epithelial tissue. These samples will be analyzed by miRNA assay to determine if there is a difference in mircroRNA expression between the two subject groups.
617 studies on the registry are indexed under Respiratory Tract Diseases; 111 are open to participants now.
This study's enrollment of 26 is below the median of 294 across 216 observational studies indexed under Respiratory Tract Diseases.
Browse Respiratory Tract Diseases studies →University of South Florida is the lead sponsor of 333 studies on the registry; 63 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 4 (24%) have results posted.
Counted across the registry records on this site, refreshed daily.
This study will be a prospective study design with a target sample size of 20. The objective of conducting it as a prospective study is to confirm that the sampling procedures and analysis methodology work as expected before attempting a larger study. We propose to have 10 study participants with nasal polyps but without AERD and 10 study participants with nasal polyps and AERD. If the results of this study are promising, larger studies with sufficient power for statistical analysis will be considered.
Exclusion Criteria:
subjects with nasal polyps and Aspirin-exacerbated respiratory disease (AERD) disease
Genetic: microRNA
subjects with nasal polyps but without Aspirin-exacerbated respiratory disease (AERD)
Genetic: microRNA
Biological samples will be taken from subjects w/ Nasal polyps \& AERD disease and subjects w/ nasal polyps without AERD. MicroRNA will be analyzed to compare genetic similarities and differences between the two study groups.
Positibe Group: 2 fold or greater will be identified as differntially expressed MiRNA.
5 total groups
Time frame: No time frame noted
Negative Group: MiRNAs are absent from both groups
5 total groups
Time frame: No time frame noted
This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of South Florida